Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis-Reference-Cited by-同舟云学术

Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis

Published:2019-01-15 Issue:4 Volume:22 Page:306-318
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

de Jong Lisa Aniek¹^ORCID,Gout-Zwart Judith J.²³,van den Bosch Marina⁴,Koops Mike¹,Postma Maarten J.¹⁵⁶^ORCID

Affiliation:

1. Unit of PharmacoTherapy, -Epidemiology & -Economics, University of Groningen, Groningen Research Institute of Pharmacy (GRIP), Groningen, the Netherlands;

2. Department of Nephrology, University of Groningen, University Medical Center Groningen (UMCG), the Netherlands;

3. Asc Academics, Groningen, the Netherlands;

4. Bayer, Mijdrecht, the Netherlands;

5. Institute for Science in Healthy Aging & healthcaRE (SHARE), University of Groningen, University Medical Center Groningen (UMCG), Groningen, the Netherlands;

6. Department of Health Sciences, University of Groningen, University Medical Center Groningen (UMCG), the Netherlands

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://tandfonline.com/doi/pdf/10.1080/13696998.2018.1563404

Reference46 articles.

1. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

2. Antithrombotic Therapy for VTE Disease

3. College voor Zorgverzekeringen. Rivaroxaban (Xarelto) bij behandeling van pulmonale embolie. CvZ; 2014 [cited 2017 Sept]. The Hague, the Netherlands. Available from: https://www.zorginstituutnederland.nl/publicaties/rapport/2014/02/18/rivaroxaban-xarelto-bij-behandeling-van-pulmonale-embolie.

4. Federation Dutch Thombotic Services (FNT). Samenvatting medische jaarverslagen. FNT; 2015 [cited 2016 Nov]. Leiden, the Netherlands. Available from: https://s3.eu-central-1.amazonaws.com/storage.topsite.nl/fnt.nl/uploads/docs/jaarverslagen/Medisch_Jaarverslag_2015.pdf.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands;Journal of Medical Economics;2024-03-12

2. Budget and health impact of switching eligible patients with atrial fibrillation to lower- dose dabigatran;Journal of Market Access & Health Policy;2023-09-04

3. A Real-World Cost-Effectiveness Analysis of Rivaroxaban versus Vitamin K Antagonists for the Treatment of Symptomatic Venous Thromboembolism: Lessons from the REMOTEV Registry;Medicina;2023-01-16

4. Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands;International Journal of Breast Cancer;2022-09-22

5. Cost-Effectiveness Analysis of Rivaroxaban in Chinese Patients With Stable Cardiovascular Disease;Frontiers in Pharmacology;2022-06-20